NCT00787072终止1 期
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD8075 in Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Safety variables (ECG, adverse events, blood pressure, pulse, body temp, safety lab)
研究概览
简要总结
The aim of this study is to assess the safety, tolerability and pharmacokinetics of single ascending oral doses of AZD8075 in healthy male volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Provision of signed, written and dated informed consent prior to any study specific procedures.
- •Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg.
- •Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for >6 months prior to study start.
排除标准
- •Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the result of the study, or the subject's ability to participate
- •Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs (vital signs (ie, supine BP and pulse) or ECG at baseline, which, in the opinion of the investigator, may put the subject at risk.
- •Participation in another investigational drug study within 3 months before Visit 2 or participation in a method development study (no drug) 1 month prior to Visit 2
研究组 & 干预措施
1
Experimental
干预措施: AZD8075 (Drug)
2
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety variables (ECG, adverse events, blood pressure, pulse, body temp, safety lab)
时间窗: Frequent sampling occasions during study days
次要结局
- PK variables(Frequent sampling occasions during study days)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
AZD5985 Single Ascending Dose StudyHealthyNCT00967356AstraZeneca72
已完成
1 期
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital HerpesRecurrent Genital Herpes Simplex Type 2NCT06698575Assembly Biosciences103
进行中（未招募）
1 期
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital HerpesRecurrent Genital Herpes Simplex Type 2NCT06385327Assembly Biosciences115
已完成
1 期
Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy VolunteersHealthy Adult SubjectsNCT02168595GlycoMimetics Incorporated28
招募中
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy SubjectsNonalcoholic Steatohepatitis (NASH)NCT06216041Changchun Intellicrown Pharmaceutical Co. LTD138